share_log

Mersana Therapeutics (NASDAQ:MRSN) Trading Up 3.7%

Defense World ·  Oct 2, 2022 02:51

Mersana Therapeutics, Inc. (NASDAQ:MRSN – Get Rating)'s stock price was up 3.7% during mid-day trading on Friday . The company traded as high as $6.66 and last traded at $6.66. Approximately 2,607 shares traded hands during trading, a decline of 100% from the average daily volume of 1,150,149 shares. The stock had previously closed at $6.42.

Wall Street Analyst Weigh In

A number of research analysts have recently issued reports on MRSN shares. Wedbush reiterated an "outperform" rating on shares of Mersana Therapeutics in a research report on Tuesday, August 9th. SVB Leerink increased their target price on Mersana Therapeutics from $13.00 to $14.00 and gave the company an "outperform" rating in a research report on Tuesday, August 9th. Finally, Robert W. Baird increased their target price on Mersana Therapeutics from $18.00 to $20.00 and gave the company an "outperform" rating in a research report on Tuesday, August 9th.

Get Mersana Therapeutics alerts:

Mersana Therapeutics Stock Up 5.3 %

The stock has a market capitalization of $656.87 million, a price-to-earnings ratio of -2.76 and a beta of 1.75. The company has a quick ratio of 3.32, a current ratio of 3.32 and a debt-to-equity ratio of 0.18. The business's 50-day moving average is $6.88 and its two-hundred day moving average is $5.05.

Mersana Therapeutics (NASDAQ:MRSN – Get Rating) last announced its quarterly earnings data on Monday, August 8th. The company reported ($0.55) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.50) by ($0.05). Mersana Therapeutics had a negative net margin of 3,057.88% and a negative return on equity of 140.57%. The business had revenue of $4.28 million for the quarter, compared to analysts' expectations of $3.18 million. Equities analysts anticipate that Mersana Therapeutics, Inc. will post -1.69 EPS for the current year.

Institutional Trading of Mersana Therapeutics

Large investors have recently bought and sold shares of the business. Victory Capital Management Inc. purchased a new position in shares of Mersana Therapeutics during the 1st quarter worth $36,000. Quantbot Technologies LP purchased a new position in Mersana Therapeutics during the 1st quarter valued at about $37,000. Washington University purchased a new position in Mersana Therapeutics during the 2nd quarter valued at about $43,000. Virtu Financial LLC purchased a new position in Mersana Therapeutics during the 1st quarter valued at about $53,000. Finally, Point72 Hong Kong Ltd purchased a new position in Mersana Therapeutics during the 4th quarter valued at about $57,000. Hedge funds and other institutional investors own 95.12% of the company's stock.

About Mersana Therapeutics

(Get Rating)

Mersana Therapeutics, Inc, a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet need. It develops XMT-1592, a Dolasynthen ADC targeting NaPi2b-expressing tumor cells, which is in phase I clinical trial for the treatment of ovarian cancer and NSCLC adenocarcinoma.

Further Reading

  • Get a free copy of the StockNews.com research report on Mersana Therapeutics (MRSN)
  • EV Battery Maker Freyr Set For Major Global Expansion
  • MarketBeat: Week in Review 9/26 – 9/30
  • This Is A Memorable Time To Buy Into Micron Technology
  • Thor Industries Hammers Out A Bottom
  • Declining Profits Challenge the CarMax Value Proposition

Receive News & Ratings for Mersana Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mersana Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment